Literature DB >> 12112732

Genetic basis of Rett syndrome.

Ignatia B Van den Veyver1, Huda Y Zoghbi.   

Abstract

The origin of Rett syndrome has long been debated, but several observations have suggested an X-linked dominant inheritance pattern. We and others have pursued an exclusion-mapping strategy using DNA from a small number of familial Rett syndrome cases. This work resulted in the narrowing of the region likely to harbor the mutated gene to Xq27.3-Xqter. After systematic exclusion of several candidate genes, we discovered mutations in MECP2, the gene that encodes the transcriptional repressor, methyl-CpG-binding protein 2. Since then, nonsense, missense, or frameshift mutations have been found in at least 80% of girls affected with classic Rett syndrome. Sixty-four percent of mutations are recurrent C > T transitions at eight CpG dinucleotides mutation hotspots, while the C-terminal region of the gene is prone to recurrent multinucleotide deletions (11%). Most mutations are predicted to result in total or partial loss of function of MeCP2. There is no clear correlation between the type and position of the mutation and the phenotypic features of classic and variant Rett syndrome patients, and XCI appears to be a major determinant of phenotypic severity. Further research focuses on the pathogenic consequences of these mutations along the hypothesis of loss of transcriptional repression of a small number of genes that are essential for neuronal function in the maturing brain. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112732     DOI: 10.1002/mrdd.10025

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  15 in total

Review 1.  The molecular pathology of Rett syndrome: synopsis and update.

Authors:  Schahram Akbarian; Yan Jiang; Genevieve Laforet
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

2.  MECP2 duplications in six patients with complex sex chromosome rearrangements.

Authors:  Amy M Breman; Melissa B Ramocki; Sung-Hae L Kang; Misti Williams; Debra Freedenberg; Ankita Patel; Patricia I Bader; Sau Wai Cheung
Journal:  Eur J Hum Genet       Date:  2010-12-01       Impact factor: 4.246

Review 3.  Ionotropic glutamate receptors & CNS disorders.

Authors:  Derek Bowie
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-04       Impact factor: 4.388

4.  Separate respiratory phenotypes in methyl-CpG-binding protein 2 (Mecp2) deficient mice.

Authors:  John M Bissonnette; Sharon J Knopp
Journal:  Pediatr Res       Date:  2006-04       Impact factor: 3.756

5.  Enhanced dense core granule function and adrenal hypersecretion in a mouse model of Rett syndrome.

Authors:  Thomas Ladas; Shyue-An Chan; Michael Ogier; Corey Smith; David M Katz
Journal:  Eur J Neurosci       Date:  2009-08-07       Impact factor: 3.386

6.  The expanding genomic landscape of autism: discovering the 'forest' beyond the 'trees'

Authors:  Valerie W Hu
Journal:  Future Neurol       Date:  2013-01-01

7.  Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice.

Authors:  Sarah E Sinnett; Emily Boyle; Christopher Lyons; Steven J Gray
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

8.  Wild-type microglia arrest pathology in a mouse model of Rett syndrome.

Authors:  Noël C Derecki; James C Cronk; Zhenjie Lu; Eric Xu; Stephen B G Abbott; Patrice G Guyenet; Jonathan Kipnis
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

9.  A mouse model of the human Fragile X syndrome I304N mutation.

Authors:  Julie B Zang; Elena D Nosyreva; Corinne M Spencer; Lenora J Volk; Kiran Musunuru; Ru Zhong; Elizabeth F Stone; Lisa A Yuva-Paylor; Kimberly M Huber; Richard Paylor; Jennifer C Darnell; Robert B Darnell
Journal:  PLoS Genet       Date:  2009-12-11       Impact factor: 5.917

Review 10.  Induced pluripotent stem cells to model and treat neurogenetic disorders.

Authors:  Hansen Wang; Laurie C Doering
Journal:  Neural Plast       Date:  2012-07-19       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.